empty

New class of haemophilia A treatment

The European Commission recently approved emicizumab (Hemlibra) to prevent bleeding episodes in people with severe haemophilia A without factor VIII inhibitors.

Roche Products and Chugai Pharma say that emicizumab is the “first new class of medicine to treat these haemophilia A patients in nearly 20 years”.

Emicizumab is already approved for haemophilia A with inhibitors to factor VIII. The new approval was based on the HAVEN 3 study, which showed that emicizumab once weekly or once every two weeks reduced treated bleeds by 96 and 97 per cent (annualised treated bleed rate [ABR] 1.5 and 1.3) respectively compared to factor VIII treatment given on-demand (ABR 38.2).

The most serious adverse reactions in the clinical trials were thrombotic microangiopathy and thrombotic events.

Recommended

Worries for brain health in low choline levels

Print health warnings on every cigarette, say Scottish researchers




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.